LEXINGTON, Mass.--(Business Wire)--
Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President
and Chief Executive Officer of Concert, will participate on the Healthcare
Private Company Panel at the Merriman Curhan Ford 6th Annual Investor Summit on
Tuesday, November 10, 2009 at 2:00 p.m. eastern time. The one day conference is
being held at the Sofitel New York in New York City.
About Concert
Concert Pharmaceuticals is a clinical stage biotechnology company focused on the
application of deuterium chemistry to create novel and differentiated small
molecule drugs. Concert`s approach leverages known activity and safety of
existing drugs to reduce time, risk and expense of drug research and
development. The Company has a broad research pipeline encompassing many
therapeutic areas including infectious disease and renal disease, among others.
Its lead development candidate is the HIV protease inhibitor CTP-518. In 2009,
Concert entered into a potential $1 billion collaboration with GlaxoSmithKline
to develop and commercialize certain deuterium-containing medicines. Founded in
2006, Concert has raised more than $110 million of venture and institutional
capital. For more information on Concert Pharmaceuticals, please visit
www.concertpharma.com.
Concert Pharmaceuticals and the CoNCERT logo are trademarks of Concert
Pharmaceuticals, Inc.
Concert Pharmaceuticals, Inc.
Justine E. Koenigsberg, 781-674-5284
Senior Director, Corporate Communications and Investor Relations
jkoenigsberg@concertpharma.com
Copyright Business Wire 2009
